OTC labeling reform: NDMA opposes "all caps" warnings in meeting with FDA.
This article was originally published in The Tan Sheet
Executive Summary
OTC LABELING REFORM: NDMA OPPOSED TO REQUIRING ALL CAPITAL LETTERS in warning statements, Nonprescription Drug Manufacturers Association Senior VP-Science & Technology William Soller, PhD, told FDA officials at a Jan. 30 "OTC feedback" meeting. "There are other ways" to display information prominently, Soller said. He suggested that FDA "can get around" using all caps "by trying...color or all-bold" lettering.